Squarepoint’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Squarepoint’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,705	Closed	-$7.07K	–	4198
2023 Q1	$7.07K	Buy	27,705 +8,840	+47%	+$7.99K	﹤0.01%	3155
2022 Q4	$22.3K	Buy	+18,865	New	+$39.7K	﹤0.01%	3101
2022 Q2	–	Sell	-50,837	Closed	-$257K	–	3577
2022 Q1	$257K	Buy	+50,837	New	+$231K	﹤0.01%	2365

Squarepoint's PEAR Position: Q2 2023 in Review

Squarepoint sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 27,705 shares — an estimated $7.07K sold.

Squarepoint first reported a position in PEAR in Q1 2022 and held it in 3 quarters. The position peaked at $257K in Q1 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Squarepoint reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Squarepoint sold 27,705 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $7.07K.
Squarepoint first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 3 quarters.
Squarepoint's Pear Therapeutics, Inc. Class A Common Stock position peaked at $257K in Q1 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.